Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Voyager Therapeutics
VYGR
Voyager Therapeutics
Gene Therapy Competition Will Curb Progress Yet Allow Modest Breakthroughs
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
10 Aug 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$8.00
57.1% undervalued
intrinsic discount
20 Aug
US$3.43
Loading
1Y
-49.6%
7D
-8.0%
Author's Valuation
US$8.0
57.1% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$8.0
57.1% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-108m
197m
2014
2017
2020
2023
2025
2026
2028
Revenue US$22.3m
Earnings US$3.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
19.64%
Biotech revenue growth rate
11.97%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.98%
Calculation
US$3.82m
Earnings '28
x
148.45x
PE Ratio '28
=
US$567.58m
Market Cap '28
US$567.58m
Market Cap '28
/
58.08m
No. shares '28
=
US$9.77
Share Price '28
US$9.77
Share Price '28
Discounted to 2025 @ 6.95% p.a.
=
US$7.99
Fair Value '25
